A Study in Participants With End-Stage Renal Disease
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to explore the effect of LY2127399 on those antibodies that are
a barrier to kidney transplant. Transplantation is currently the definitive treatment for
End-Stage Renal Disease (ESRD), providing prolonged survival and improved quality of life.